Innovate UK funding as company invests in pandemic-driven expansion 13 APR 2021 ATDBio, a leader in complex oligonucleotide synthesis, has been awarded funding by Innovate UK to develop a new…
Read More
Company’s technologies and drug-hunting expertise now responsible for world’s first and second AI-designed drugs to enter Phase I testing Exscientia, a leading artificial intelligence (AI) driven pharmatech company, today announced…
Funding will support the company to achieve first-in-human data Oxford, UK, 8th April 2021 – Oxford Endovascular, a pioneering British MedTech company and spinout from Oxford University, is developing a…
Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation, today announces the appointment of Pierre Legault BAA, MBA, CA, CPA as Chairman…
Oxford, UK – Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer,…
Second occupier for Bellhouse Building at The Oxford Science Park Oxford, UK, March 8 2021 – Sitryx, a company which is focused on regulating cell metabolism to develop disease-modifying therapeutics…
Proceeds to further accelerate AI drug discovery platform and pipeline Exscientia, a clinical stage pharmatech pioneering the use of artificial intelligence (AI) to design new drugs, today announced that funds…
WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers PHILADELPHIA and OXFORD, March 2, 2021 – WuXi AppTec, a leading global provider of…
Investment will fund Phase 2 human clinical studies evaluating Oxular’s 12-month treatment for diabetic macular edema, and accelerate development of early-product pipeline OXFORD, UK, 1 March 2021 – Oxular Limited (“Oxular”),…
18th Feb 2021 Financing round significantly oversubscribed by both new and existing investors Proceeds enable advancement of our exosome therapeutics into the clinic and expansion of our world-leading exosome platform…
Exscientia & University of Oxford announce partnership to develop treatments for Alzheimer’s disease
Neuroinflammation collaboration targeting inflammasome steps-up-the-pace in race for Alzheimer’s disease medicines that alleviate the burden of devastating disease Oxford: Exscientia, a leading AI Drug Discovery company, has today announced its…
Immunocore Holdings plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of…
Oxford, UK – 1st February 2021 – Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of…
Mobile COVID-19 testing laboratories containing Oxford Nanopore’s LamPORE test are now being deployed in a pilot programme, to support testing efforts, including in remote locations. There are four mobile LamPORE…
Ingelheim, Germany and Oxford and London, UK, January 12th, 2021 – Boehringer Ingelheim and Enara Bio, today announced that they have entered into a strategic collaboration and licensing agreement to research…